



Inflammatory Bowel Disease

TRANSLATING BASIC SCIENCE INTO CLINICAL PRACTICE

Edited by

Stephan R. Targan

Fergus Shanahan

Loren C. Karp

 **WILEY-BLACKWELL**

Contents

List of Contributors

Preface

1 Introduction: the Science and the Art of Inflammatory Bowel Disease

2 Heterogeneity of Inflammatory Bowel Diseases,

Introduction

Classical clinical heterogeneity

Laboratory heterogeneity

Genetic heterogeneity

Biomarkers of disease

Heterogeneity of treatment responses

Evidence of IBD heterogeneity from animal models

Harnessing heterogeneity - the future of IBD research

Conclusion

References

3 Epidemiology of Inflammatory Bowel Disease: the Shifting Landscape

Introduction

The emergence of Crohn's disease as the most common form of IBD

The demographics of IBD

Conclusion

References

4 Genetics of Inflammatory Bowel Disease: How Modern Genomics Informs Basic, Clinical and Translational Science

Introduction

Methods used in the study of complex genetics

Identification of susceptibility genes in IBD

MHC region

Toll-like receptor genes

Recent advances in UC genetics

Conclusion

References

5 In Vivo Models of Inflammatory Bowel Disease

Introduction

Innate immune models - epithelial

Innate immune models - myeloid and other

Adaptive immune models - effector cell function

Adaptive immune models - aberrant T cell development or activation

Models of impaired regulation

Models of spontaneous IBD

Discussion

Environmental factors

Conclusion

References

6 Factors Affecting Mucosal Homeostasis: a Fine Balance,

Introduction

The gastrointestinal immune response - the inductive site

The gastrointestinal immune response - the effector site

General mechanisms of oral tolerance

The relationship between commensal bacteria and the mucosal immune system

Conclusion

References

7 Innate Immunity and its Implications on Pathogenesis of Inflammatory Bowel Disease

Introduction

Overview of the innate immune system

Expression of TLRs in health and disease

General role of TLRs and Nods: maintenance of barrier function, induction

of IgA and expression of antimicrobial peptides

Expression of Nods in health and disease

Link between innate immunity and adaptive immunity in the pathogenesis of IBD

Innate immunity links genetic susceptibility to IBD and commensal bacteria

Conclusion and implications for therapy of IBD

References

8 Adaptive Immunity: Effector and Inhibitory Cytokine Pathways in Gut Inflammation,

Introduction

CD4⁺ T cells accumulate in IBD tissue

TGF β as the master regulator of inflammation in the gut in health and disease

Th17 cells, the link between TGF β and IL-21

Conclusion

References

9 Host Response to Bacterial Homeostasis

Introduction

The microbial bionetwork

The intestinal epithelial barrier

[Immune cell types](#)

[The intestinal epithelial cell as an antigen-presenting cell](#)

[CD1d, a novel ligand on IECs](#)

[Mechanisms of innate immunity throughout the intestinal mucosa](#)

[Chemokines](#)

[References](#)

[10 Cytokines and Chemokines in Mucosal Homeostasis](#)

[Introduction](#)

[Pro-inflammatory cytokines](#)

[Unclassified cytokines](#)

[Chemokines](#)

[Conclusion](#)

[Acknowledgments](#)

[References](#)

[11 The Role of the Vasculature in Chronic Intestinal Inflammation](#)

[Introduction](#)

[Lymphocyte trafficking in chronic gut inflammation](#)

[Angiogenesis and IBD](#)

[Angiogenic mediators in IBD and experimental colitis](#)

[Anti-angiogenic gene expression and therapeutics in IBD and experimental colitis](#)

Thrombosis and inflammatory bowel disease

Microvascular blood flow in intestinal inflammation

Acknowledgments

References

12 Biological Basis of Healing and Repair in Remission and Relapse

Introduction

Factors regulating mucosal repair and protecting from injury in the intestine

Non-peptidyl factors

Peptide growth factors and cytokines

EGF receptor ligand family

The transforming growth factor beta family

Vascular endothelial growth factor (VEGF, “vasculotropin”)

Fibroblast growth factor family

Hepatocyte growth factor (HGF, scatter factor)

Gastrointestinal hormones as growth factors

Glucagon-like peptide-2 (GLP-2)

Insulin-like growth factors (somatomedins)

Trefoil peptides, trefoil factor family (TFF)

Extracellular matrix (ECM) molecules

Regulation of mucosal repair by subepithelial cell populations and stroma

Gastrointestinal stem cells and the stem cell “niche”

Novel approaches to stimulating repair

Conclusions

References

13 The Bidirectional Relationship of Gut Physiological Systems and the Mucosal Immune System

Introduction

Part I. The effect of immune activation and inflammation on gastrointestinal physiology

Part II. The role of physiological systems in modulating intestinal inflammation

References

14 Extraintestinal Consequences of Mucosal Inflammation

Introduction

Acute phase proteins

Hematologic consequences of intestinal inflammation

References

15 Ulcerative Colitis and Ulcerative Proctitis: Clinical Course and Complications

Introduction

Potential confounders in UC natural history studies

Disease extent

Extent of UC at diagnosis and follow-up

The dynamics of disease extent

Severity of attacks of UC

Acute severe UC (ASUC)

Course of the disease

Ulcerative proctitis - a separate entity?

Pediatric and adolescent UC

Other factors that may influence UC natural history

Colectomy

Colorectal cancer in UC

Surveillance colonoscopy

Mortality from colorectal cancer

Does health education change the natural history of UC?

Conclusion

References

16 Crohn's Disease: Clinical Course and Complications

Introduction

Clinical presentations

Complications

Systems of disease classification

Serologic profiles

Endoscopic and radiographic features

Natural History and Prognosis

Quality of life

Conclusion

References

17 Practical Inflammatory Bowel Disease Pathology in Patient Management

Introduction

The initial biopsy differential diagnosis of IBD

Normal microscopic appearances which may cause diagnostic difficulty

Normal colonoscopic findings in patients with diarrhea

Biopsies of ulcers

Biopsies of polyps

Colonoscopic finding of colitis limited to the sigmoid colon

Variation in microscopic appearances in ulcerative colitis

Mucosal biopsies in Crohn's disease

The appendix in IBD

Mimicry of Crohn's disease by ulcerative colitis

Upper gastrointestinal tract biopsies

Chronic IBD unclassified and indeterminate colitis

Backwash ileitis in ulcerative colitis

Colitis-associated neoplasia

Conclusion

References

18 The Role of Endoscopy in Diagnosis and Treatment of Inflammatory Bowel Disease

Introduction

Foregut: overview

Foregut: oral cavity

Foregut: esophagus

Foregut: stomach

Foregut: duodenum

***Foregut endoscopy:
esophagoduodenoscopy***

Midgut: overview

***Midgut endoscopy: push enteroscopy,
capsule endoscopy, single and double
balloon enteroscopy***

Biliary tract: overview

***Biliary tract endoscopy: endoscopic
retrograde cholangiopancreatography,
choledochoscopy, intraductal ultrasound
and conventional endoscopic ultrasound***

Hindgut: overview

***Hindgut endoscopy: colonoscopy and
ileoscopy***

***Hindgut endoscopy: colonoscopic disease
activity monitoring***

Hindgut endoscopy: colonoscopic cancer surveillance

Hindgut endoscopy: flexible sigmoidoscopy

Conclusion

References

19 Imaging in Inflammatory Bowel Disease: Computed Tomography and Magnetic Resonance Enterography, Ultrasound and Enteroscopy

Introduction

Ultrasound

CT enterography and enteroclysis

MR enterography and enteroclysis

Other radiographic measures of disease activity

What information does the gastroenterologist seek from enterography?

Conclusion

References

20 New Diagnostic Approaches: Integrating Serologics, Endoscopy and Radiology and Genomics

Introduction

Biological markers of inflammation

Genetic markers

Functional genomics and IBD

Conclusion
References

21 Considerations in the Differential Diagnosis of Colitis

Introduction

Infectious colitis and proctitis

Other causes of colitis

Conclusion

References

22 Disease Management in Chronic Medical Conditions and its Relevance to Inflammatory Bowel Disease,

What is Disease Management?

Why was a management solution needed for healthcare?

What was the Disease Management solution originally proposed?

Why were economic evaluations an important driver to the development of Disease Management?

Can Disease Management really lower healthcare costs?

Issues with economic analysis of Disease Management programs

Factors that influence drug use and cost

Why is Disease Management important for physicians and vice versa?

Decision-making in Disease Management needs accepted guidelines

Does Disease Management work when guidelines are applied?

How can Disease Management best be implemented?

What is the evidence for Disease Management programs in IBD?

Conclusion

References

23 Outcomes, Disease Activity Indices and Study Design

Introduction

Randomization

Blinding/masking

Placebo versus active comparator

Sample size considerations

Superiority versus equivalence trials

Induction and maintenance trials

Outcome measures specific to IBD trials

Quality of life

Optimizing clinical trial efficiency

Definition of response and remission

Measuring safety in clinical trials

Balancing efficacy and safety

References

24 Non-targeted Therapeutics for Inflammatory Bowel Diseases

Introduction

Multi-site targeted therapy by glucocorticoids

Peroxisome proliferator-activated receptor gamma (PPAR γ)

Inhibition of NF- κ B-mediated transactivation as a central target of IBD therapy

References

25 Targeted Treatments for Inflammatory Bowel Diseases,

Introduction

IBD pathogenesis

Classes of site-specific therapeutics

Current and emerging site-specific therapeutics for IBD

Limitations of site-specific agents

Conclusion

References

26 Therapeutic Manipulation of the Microbiota in Inflammatory Bowel Disease: Antibiotics and Probiotics

Introduction

The microbiota in inflammatory bowel disease

Antibiotic therapy of inflammatory bowel disease

Probiotics in inflammatory bowel disease

Conclusion

References

27 The Role of Nutrition in the Evaluation and Treatment of Inflammatory Bowel Disease

Dietary factors in inflammatory bowel disease causation

Intervention studies

Enteral feeding as primary therapy for CD

Enteral nutrition in the prevention of post-operative recurrence of Crohn's disease

Nutritional deficiencies in IBD

Intestinal failure/short bowel syndrome

References

28 Therapeutic Approaches to the Treatment of Ulcerative Colitis

Introduction

Pretreatment evaluation of the patient

Goals of treatment

Treatment indications and algorithm and specific treatment approaches

Conclusion

References

29 Surgical Considerations for Ulcerative Colitis

Introduction

Elective procedures for ulcerative colitis

Institute results on surgical procedures for ulcerative colitis

Special considerations

Conclusion

References

30 Clinical Characteristics and Management of Pouchitis and Ileal Pouch Disorders

Introduction

Cuffitis

Crohn's disease of the pouch

Irritable pouch syndrome

Conclusion

Acknowledgment

References

31 Therapeutic Approaches to the Treatment of Crohn's Disease,

Introduction

Predicting the pattern of Crohn's disease at diagnosis

Epidemiology of relapse

Treatment of active Crohn's disease

Active colonic disease

Management of medically induced remission

Conclusion

References

32 Surgical Considerations for the Patient with Crohn's Disease/Perianal Crohn's Disease,

Introduction

Indications and timing of surgery

General considerations

Surgery for small bowel Crohn's disease

Surgery for gastroduodenal disease

Surgery for large bowel disease

Conclusion

References

33 Diagnostic and Therapeutic Approaches to Postoperative Recurrence in Crohn's Disease

Introduction

Postoperative recurrence of ileal Crohn's disease

Assessment of postoperative recurrence

Risk stratification for early postoperative recurrence

Endpoints in clinical trials

Aminosalicylates: sulfasalazine and mesalamine

Purine analogues

Nitroimidazole antibiotics

Probiotics

Algorithm for management of clinical recurrence of Crohn's disease after curative resection

Strategies for the future: where to go from here?

New developments: medical prophylaxis

References

34 Molecular Alterations Associated with Colitis-associated Colon Carcinogenesis

Introduction

Causation: genes versus environment

Molecular pathways of sporadic versus colitis-associated carcinogenesis

Chromosomal instability (CIN)

Microsatellite instability

Promoter methylation

Potential clinical application of molecular markers

The problem of polypoid dysplasia in IBD

New molecular screening approaches

Acknowledgment

References

35 Cancer Surveillance in Inflammatory Bowel Disease

Introduction

Risk of colorectal cancer in ulcerative colitis

Risk factors for colorectal cancer in colitis

Primary sclerosing cholangitis

Clinicopathological characteristics of cancer in colitis

What can be done about the risk of cancer in colitis?

References

36 Liver Diseases in Patients with Inflammatory Bowel Diseases

Hepatobiliary complications of inflammatory bowel diseases

Prevalence of liver disease

Primary sclerosing cholangitis

Epidemiology

Etiology

Laboratory investigations

Radiographic features

Pathological features and staging of PSC

Natural history

The relationship of primary sclerosing cholangitis with inflammatory bowel disease

Small duct primary sclerosing cholangitis (SD-PSC)

Hepatocellular carcinoma

Autoimmune hepatitis

Fatty change

Cirrhosis

Gallstones

Amyloidosis

Granulomas

Drug-induced hepatitis

Liver abscess

Primary biliary cirrhosis

Budd-Chiari syndrome

References

37 Conditions of the Eyes and Joints Associated with Inflammatory Bowel Disease,

Introduction

Arthritis

Environmental factors

Management of IBD arthritis

Ocular manifestations of IBD

References

38 Dermatologic Conditions Associated with Inflammatory Bowel Diseases

Introduction

**Orocutaneous manifestations of
inflammatory bowel disease**

Cutaneous manifestations of inflammatory bowel disease

Conclusion

References

39 Fertility and Pregnancy in Inflammatory Bowel Diseases

Introduction

Genetics and inheritance

Fertility and sexual function

Pregnancy outcomes

Disease activity

Labor and delivery

Medications

Conclusion

References

40 Inflammatory Bowel Disease in the Pediatric Population

Introduction

Epidemiology of pediatric inflammatory bowel disease

Clinical presentations specific to the pediatric population

Diagnostic approaches

Disease activity markers

Therapeutic approaches for the pediatric IBD patient

Assessment and management of malnutrition

Detection and management of bone disease

Psychosocial functioning in pediatric IBD

Surgical considerations

Transition to adult care

References

41 Lymphocytic and Collagenous Colitis

Background

Incidence

Etiologic theories and associations

Clinical presentation and differential diagnosis

Pathology

Histopathologic features

Pathophysiology

References

42 Inflammatory Bowel Disease Microcirculation and Diversion, Diverticular and Other Non-infectious Colitides,

Introduction

The gut vasculature

The microvasculature in IBD

Targeting the microvasculature for therapy in IBD

Distinct forms of colitis which may mimic IBD

Conclusion

References

43 Clostridium Difficile-associated Diarrhea

Introduction

Clostridium difficile

Risk factors

Immune factors and host defense

Epidemiology of C. difficile infection

Pathology

Clinical features of C. difficile infection

Prevention

References

44 Colitides of Infectious Origins

Introduction

Epidemiology of infectious colitis

Etiology of infectious colitis

Non-specific colitis and intestinal infection

References

45 Recent Advances in the Understanding of HIV and Inflammatory Bowel Diseases,

Introduction

Epidemiology, natural history and treatment of HIV infection

Mucosal immunopathogenesis of HIV infection

HIV infection and inflammatory bowel disease

Conclusion

References

46 Bone Metabolism and Inflammatory Bowel Disease,

The interplay between factors that affect bone and immune homeostasis

BMD in IBD

Fracture risk in IBD

Treating osteoporosis in patients with IBD

Conclusion

References

47 Comprehensive Approach to Patient Risk: Risks Versus Benefits of Immunomodulators and Biologic Therapy for Inflammatory Bowel Disease,

Introduction

Risk assessment

Communicating risks of IBD therapy to patients

Conclusion

References

48 Complementary Medicine

Introduction

Use of CAM

Review of efficacy of CAM in human IBD

Evaluating the efficacy of CAM in IBD

Herbal therapies

Other CAM modalities

Possible modes of action of CAM

Side effects of CAM

Regulation

Conclusion

References

49 Legal Pitfalls in Treating Inflammatory Bowel Disease Patients

Introduction

Long-term management of the IBD patient

Clinical guidelines

Drugs

Acute colitis

Delayed diagnosis of Crohn's disease

Cancer surveillance

Surgical issues

Osteoporosis

Avascular necrosis

Intestinal tuberculosis

Acknowledgments

References

**50 The Present and Future of
Research and Treatment of
Inflammatory Bowel Disease**

**Bidirectional translation of rodent and
genetic research**

Definition of relevant bacterial antigens

Intelligently designed clinical trials

“Reagent grade” populations

Reference

Index

Colour plate can be found facing page

Inflammatory Bowel Disease

**Translating basic science into
clinical practice**

EDITED BY

STEPHAN R. TARGAN MD

Director, Cedars-Sinai Division of Gastroenterology and
Inflammatory Bowel and Immunobiology Research Institute
Professor of Medicine, UCLA School of Medicine
Los Angeles, CA, USA

FERGUS SHANAHAN MD

Professor and Chair
Department of Medicine and Director, Alimentary Pharmabiotic Centre
University College Cork
National University of Ireland;
Professor
Department of Medicine
Cork University Hospital
Cork, Ireland

LOREN C. KARP

Research Program Science Advisor
Inflammatory Bowel and Immunobiology Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA, USA

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2010, © by Blackwell Publishing Ltd

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office:

John Wiley & Sons Ltd, The Atrium, Southern Gate,
Chichester, West Sussex PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex PO19
8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any